Items Tagged ‘AML liposome-encapsulated’

August 7th, 2017

FDA Approves Vyxeos for Adults with Poor Prognosis AML


The U.S. Food and Drug Administration granted regular approval to a liposome-encapsulated combination of daunorubicin and cytarabine for the treatment of adults with newly-diagnosed therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC), two types of AML having a poor prognosis. This is the first FDA-approved treatment specifically for patients with t-AML or AML-MRC. Approval […]

View full entry

Tags: AML liposome-encapsulated, cytarabine, daunorubicin, Myelodysplastic Syndrome, News, Vyxeos